Overactivation of the kynurenine pathway, particularly IDO, is associated with an unfavorable prognosis in various cancer types, including gastrointestinal cancers, gynecological cancers, hematological malignancies, breast cancer, lung cancer, glioma, melanoma, prostate cancer, and pancreatic cancer. Here, IDO1 is linked to central nervous system cancer.